Should we develop screens for multi-drug antibiotic tolerance?

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 7, 2016, Pages 613-616

  Van den Bergh, Bram ^a   Michiels, Joran Elie ^a   Fauvart, Maarten ^b   Michiels, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b IMEC   (Belgium)

Author keywords

antibiotic crisis; antibiotic resistance; bacterial persistence; multi drug tolerance; persisters; Tolerance

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; DAPTOMYCIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL MUTATION; BIOFILM; DRUG SCREENING; DRUG TOLERANCE; DRUG TRANSPORT; DRUG TREATMENT FAILURE; EDITORIAL; ERADICATION THERAPY; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGEN CLEARANCE; SINGLE NUCLEOTIDE POLYMORPHISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG TOLERANCE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84973659239     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2016.1194754     Document Type: Editorial

References (38)

1. World Health Organization (WHO). Antimicrobial resistance: global report on surveillance 2014. [cited 2016 Apr 19]. Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1.
2. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. [cited 2016 Apr 19]. Available from: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
3. Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. [cited 2016 Apr 19]. Available from: http://amr-review.org/sites/default/files/Report-52.15.pdf.
4. L.Lin, P.Nonejuie, J.Munguia, et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant Gram-negative bacterial pathogens. EBioMedicine. 2015;2(7):690–698.
5. J.J.W.Bigger Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet. 1944;244(6320):497–500.
6. R.M.McCune, R.Tompsett. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med. 1956;104(5):737–762.
7. R.O.Brennan, D.T.Durack. Therapeutic significance of penicillin tolerance in experimental streptococcal endocarditis. Antimicrob Agents Chemother. 1983;23(2):273–277.
8. R.Novak, B.Henriques, E.Charpentier, et al. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature. 1999;399(6736):590–593.
9. E.Tuomanen, D.T.Durack, A.Tomasz. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother. 1986;30(4):521–527.
10. C.K.Okoro, R.A.Kingsley, M.A.Quail, et al. High-resolution single nucleotide polymorphism analysis distinguishes recrudescence and reinfection in recurrent invasive nontyphoidal Salmonella Typhimurium disease. Clin Infect Dis. 2012;54(7):955–963.
11. K.Ejrnaes, D.Sandvang, B.Lundgren, et al. Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. J Clin Microbiol. 2006;44(5):1776–1781.
12. K.S.Kim, E.L.Kaplan. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr. 1985;107(5):681–684.
13. J.A.McCullers, B.K.English, R.Novak. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis. 2000;181(1):369–673.
14. E.Maisonneuve, K.Gerdes. Molecular mechanisms underlying bacterial persisters. Cell. 2014;157(3):539–548.•• Crisp and clear review on molecular mechanisms of bacterial persistence with a focus on the type II TA systems.
15. M.Fauvart, V.N.De Groote, J.Michiels. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol. 2011;60(6):699–709.
16. A.L.Spoering, K.I.M.Lewis. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol. 2001;183(23):6746–6751.
17. S.Helaine, A.M.Cheverton, K.G.Watson, et al. Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science. 2014;343(6167):204–208.• This report nicely shows the in vivo relevance of Salmonella persisters as they are induced in macrophages and remain present in immune organs of treated mice.
18. P.Kaiser, R.R.Regoes, T.Dolowschiak, et al. Cecum lymph node dendritic cells harbor slow-growing bacteria phenotypically tolerant to antibiotic treatment. PLoS Biol. 2014;12(2):e1001793.
19. L.W.Goneau, N.S.Yeoh, K.W.MacDonald, et al. Selective target inactivation rather than global metabolic dormancy causes antibiotic tolerance in uropathogens. Antimicrob Agents Chemother. 2014;58(4):2089–2097.
20. K.Stepanyan, T.Wenseleers, E.A.Duéñez-Guzmán, et al. Fitness trade-offs explain low levels of persister cells in the opportunistic pathogen Pseudomonas aeruginosa. Mol Ecol. 2015;24(7):1572–1583.
21. L.R.Mulcahy, J.L.Burns, S.Lory, et al. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol. 2010;192(23):6191–6199.
22. O.Fridman, A.Goldberg, I.Ronin, et al. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature. 2014;513(7518):418–421.•• By imposing cultures of E. coli to frequent ampicilin treatment upon dilution in stationary phase, Fridman and colleagues quickly obtained mutants containing individual single-nucleotide polymorphisms that showed extremely increased tolerance by increasing the lag according to the imposed duration of treatment.
23. L.Mechler, A.Herbig, K.Paprotka, et al. A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59(5):5366–5376.
24. B.Van den Bergh, J.E.Michiels, T.Wenseleers, et al. Frequency of antibiotic application drives rapid evolutionary adaptation of Escherichia coli persistence. Nat Microbiol. 2016;1:16020.•• Similar to [22] but with aminoglycoside treatments in stationary phase. They extend previous observations to prove a long-standing hypothesis that persister levels should correlate with the different treatment frequencies to which evolving cultures were exposed in the past.
25. J.E.Michiels, B.Van den Bergh, N.Verstraeten, et al. In vitro emergence of high persistence upon periodic aminoglycoside challenge in the ESKAPE pathogens. Antimicrob Agents Chemother. 2016;60(8). doi:10.1128/AAC.00757–16.• Further expanding on [24] by showing the generality of the evolutionary process to clinically more relevant species of the ESKAPE pathogens group.
26. B.R.Levin, D.E.Rozen. Non-inherited antibiotic resistance. Nat Rev Microbiol. 2006;4(7):556–562.
27. N.R.Cohen, M.A.Lobritz, J.J.Collins. Microbial persistence and the road to drug resistance. Cell Host Microbe. 2013;13(6):632–642.•• A review ahead of its time on bacterial persistence focusing on the potential link between persistence and the generation drug resistance.
28. L.E.Fleck, E.J.North, R.E.Lee, et al. A screen for and validation of prodrug antimicrobials. Antimicrob Agents Chemother. 2014;58(3):1410–1419.
29. J.Haaber, C.Friberg, M.McCreary, et al. Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure. MBio. 2015;6(1):e02268–14.
30. A.N.Verstraeten, W.J.Knapen, C.I.Kint, et al. Obg and membrane depolarization are part of a microbial bet-hedging strategy that leads to antibiotic tolerance. Mol Cell. 2015;59(1):9–21.•• This paper shows how a central and conserved GTPase acts as a central hub for persistence by inducing a typ I TA system, critically dependent on the stringent response but not on type II TA systems or the lon protease/polyphosphate pathway.
31. T.Vogwill, A.C.Comfort, V.Furió, et al. Persistence and resistance as complementary bacterial adaptations to antibiotics. J Evol Biol. Forthcoming 2016. doi:10.1111/jeb.12864.
32. M.A.Schumacher, P.Balani, J.Min, et al. HipBA–promoter structures reveal the basis of heritable multidrug tolerance. Nature. 2015;524(7563):59–64.•• This study describes at a structural level how variants in HipA toxin cause high persistence and furthermore proves the relevance of these mutations in clinical isolates of E. coli.
33. K.R.Allison, M.P.Brynildsen, J.J.Collins. Heterogeneous bacterial persisters and engineering approaches to eliminate them. Curr Opin Microbiol. 2011;14(5):593–598.• A concise review on persistence with focus on potential antipersister treatment options.
34. B.W.Kwan, N.Chowdhury, T.K.Wood. Combatting bacterial infections by killing persister cells with mitomycin C. Environ Microbiol. 2015;17(11):4406–4414.
35. V.Defraine, J.Scheurmans, B.Grymonprez, et al. Efficacy of Artilysin® Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(6):3480–3488.
36. B.P.Conlon, E.S.Nakayasu, L.E.Fleck, et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature. 2013;503(7476):365–370.•• Describes nicely how the application of ADEP4 to activate ClpP in a random way, creating a protease that kills persisters.
37. M.A.Orman, M.P.Brynildsen. Persister formation in Escherichia coli can be inhibited by treatment with nitric oxide. Free Radic Biol Med. 2016;93:145–154.
38. Y.Pu, Z.Zhao, Y.Li, et al. Enhanced efflux activity facilitates drug tolerance in dormant bacterial cells. Mol Cell. 2016;62(2):284–294.